Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

NovoStent gets new CEO: Ray Martin, PhD, will replace the firm's founder and primary inventor, Michael Hogendijk, as President & CEO. Hogendijk will continue as chief technical officer. Martin was most recently VP-business development of TriVascular, which was acquired by Boston Scientific in April. He also has held executive positions at Bard and W.L. Gore, where he co-invented the Gore Viabahn and Hemobahn stent grafts. NovoStent recently raised $3.1 mil. for its first human trial evaluating its self-expanding helical stent in the superficial femoral artery, scheduled to start in 2006 (1"The Gray Sheet" Sept. 5, 2005, p. 14)...
Advertisement

Related Content

Financings In Brief
Financings In Brief
People In Brief
Advertisement
UsernamePublicRestriction

Register

MT022876

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel